 |
|
|
| |
Daclatasvir/Asunaprevir/Beclabuvir
Fixed-Dose Combination in Treatment-Naive and
Interferon-Experienced Japanese Patients With
HCV Genotype 1 Infection: UNITY-3 Study
|
| |
| |
Reported by Jules Levin
25th Conference of the Asian Pacific Association for the Study of the Liver:
APASL 2016, Tokyo, Japan
Chayama K,1 Toyota J,2 Karino Y,2 Suzuki F,3 Ikeda F,4 Ido A,5 Tanaka K,6 Takaguchi K,7 Naganuma A,8 Tomita E,9 Fujiyama S,10 Inada Y,11 Yoshiji H,12 Watanabe H,13
Ishikawa H,13 Hu W,14 McPhee F,14 Linaberry M,14 Yin PD,14 Swenson ES,14 Kumada H3
1Hiroshima University, Hiroshima, Japan; 2Sapporo-Kosei General Hospital, Sapporo, Japan;
3Toranomon Hospital, Tokyo, Japan; 4Okayama University, Okayama, Japan;
5Kagoshima University, Kagoshima, Japan; 6Yokohama City University Medical Center, Yokohama, Japan;
7Kagawa Prefectural Central Hospital, Takamatsu City, Japan; 8Takasaki General Medical Center,
Takasaki, Japan; 9Gifu Municipal Hospital, Gifu, Japan; 10Kumamoto Shinto General Hospital, Kumamoto, Japan; 11Miyazaki Medical Center Hospital, Miyazaki, Japan; 12Nara Medical University, Kashihara, Japan;
13Bristol-Myers K.K., Tokyo, Japan; 14Bristol-Myers Squibb, Princeton, NJ, USA
|
| |
|
|
|
|
|
